We have an active research program covering a wide range of topics related to oral and parenteral drug delivery. Listed below are selected references and patents describing work that has been done in our laboratories and those of our collaborators:
Kim, J.S., S. Mitchell, P. Kijek, Y. Tsume, J.M. Hilfinger, and G.L. Amidon, The Suitability of an In Situ Perfusion Model for Permeability Determinations: Utility for BCS Class 1 Biowaiver Requests. Mol Pharm, (2006);3(6)686-94.
International Bioequivalence Standards: A NEW ERA, (editors) Amidon GL, Lesko L, Midha K, Shah V, Hilfinger JM, TSRL, Inc. Ann Arbor, (2006).
Lipka E and Amidon GL: Setting bioequivalence requirements for drug development based on preclinical data: Optimizing oral drug delivery systems. J. Control. Rel. 62(1-2), p. 41-50, (1999)
Li L, Kim JS, Heimbach T, Fleisher D. Region-Dependent Metabolism and Permeability of Indinavir in Rat Intestine. Pharm. Res. 15: (1999).
Siersma CA, Kim JS, Clark L, Walton J, and Amidon GL. Evaluation of a Rank Order of the Permeability Ratios of Various Compounds for Categorization into the Biopharmaceutics Classification System. Pharm. Res. 15: (1999).
J.R. Crison, E. Lipka, G.L. Amidon: Effect of release rate and permeability on fraction dose absorbed of a highly soluble drug in the ascending colon. Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 25, (1998)
Amidon GL. Biopharmaceutics classification system: Interview with Prof. Gordon Amidon, Dissoln. Tech., Nov. (1998)
Langguth P, Amidon GL, Lipka E, Spahn-Langguth H, Gastrointestinal Transport Processes: Potentials for Stereoselectivities at Substrate-Specific and Nonspecific Epithelial Transport Systems. In: “The Impact of Stereochemistry on Drug Development and Use”, ed. Aboul-Enein HY and Wainer, IW, John Wiley & Sons, Inc. (1997)
Lipka E, Hilfinger JM, Siersma CA, Crison JR, Ridgewell RE, Amidon GL: Evaluation of imiquimod and analogues with respect to their oral delivery potential. Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 24, p.337 (1997)
Walter E, Janich S, Roessler BJ, Hilfinger JM, Amidon GL HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. Journal of Pharmaceutical Science, 85(10):1070-6, (1996).
Yu LX, Lipka E, Crison JR, Amidon GL: Transport Approaches to the Biopharmaceutical Design of Oral Drug Delivery Systems: Prediction of Intestinal Absorption. Advan. Drug Deliv. Rev. 19:359-376, (1996)
E. Lipka, J.S. Kim, J.R. Crison, S. Roy, G.L. Amidon, “Oral Absorption of the HIV-Protease Inhibitor AG1343: A Function of Site Specific Permeability and pH Dependent Solubility”, AAPS National Meeting, (1996).
Gibbons, J.A., Lipka, E., Siersma, C.A., Crison, J.R., Breakman, R.A., Amidon GL: Absorption of Drugs into Prehepatic Blood: Correlation between In Situ Absorption and Effective Permeability in Humans. Pharm.Res. 13(9): S-416 (1996).
Lipka E, Yu L, Liu D, Crison JR, Amidon GL: Evaluation of the Intestinal Permeabilities of b-Blocker Drugs and Their Potential for Oral Controlled Release. Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 22, p.366 (1995)
Amidon GL, Lennernas H, Shah V, Drison J. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of In Vitro Drug Product Dissolution and In Vivo bioavailability (1995) Pharm. Res. 12 (3) 413-20.
Lennernas H, Crison J, Amidon GL. Permeability and Clearance Views of Drug Absorption: A Commentary. (1995) J. Pharmacokinet. Biopharm. 23 (3) 333-43.
J-S Kim, V.C. Yang and G.L. Amidon, Structure-permeability and structure-activity relationship for ACE inhibitors, Abstract, Pharm. Res., 8, S-56 (Nov 1991) Washington, DC.
